You have been successfully logged out.
Evolving DLBCL Treatment: Practical Guidance to Optimise Patient Outcomes
The availability of YESCARTA®▼ (axicabtagene ciloleucel) for eligible patients with R/R DLBCL within 12 months from first-line chemoimmunotherapy is a milestone in this setting. Dr Sridhar Chaganti, Dr Kate Cwynarski and Dr Michael Jain outline these important changes to the DLBCL treatment landscape, explain the data that drove this decision and offer guidance on providing optimal treatment to patients.
Chair’s introduction: Evolving DLBCL pathway and guidelines
Dr Sridhar Chaganti discusses how DLBCL guidelines could evolve in line with the treatment landscape and outlines why second-line CAR T is a potential lifeline for certain patients with R/R DLBCL.
(Webinar recorded June 2023. Full video: <10 minutes)
Clinical decision making in the real world
Dr Kate Cwynarski provides key information on clinical decision-making in the treatment of patients with R/R DLBCL. A clinical case highlights the importance of CAR T early in the treatment pathway, and patient eligibility is discussed in terms of NICE second-line recommendations and ZUMA-7 subgroup analyses data.
(Webinar recorded June 2023. Full video: <10 minutes)
US YESCARTA® experience
Dr Michael Jain looks at how the US has been using YESCARTA® in second-line DLBCL patients including discussions surrounding prior lines of therapy, tumour genomics, outcomes and bridging approaches.
(Webinar recorded June 2023. Full video: <25 minutes)
April 2025 UKI-YES-0116
Adverse events should be reported
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.